Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deep Breeze launches radiation-free pulmonary imaging system in US

This article was originally published in Clinica

Executive Summary

Deep Breeze has launched its lung imaging system, VRIxp, in the US. The noninvasive radiation-free device employs vibration response imaging (VRI) technology, which uses lung sounds to create images. It records the sounds of the patient's breath, using sensors applied to the back, and an algorithm converts these data into images. It is designed for patients who arrive at the emergency department with dyspnoea, and can help diagnose several lung conditions including chronic obstructive pulmonary disease and asthma, as well as congestive heart failure. The FDA granted 510(k) clearance for the device in 2007 (www.clinica.co.uk, 24 August 2007), and Or-Akiva, Israel-based Deep Breeze CE marked it for sale in Europe in 2005 (www.clinica.co.uk, 7 October 2005).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT095697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel